New treatments for diabetes that activate insulin receptors
Official title: Beyond insulin: Next-generation modulators of insulin receptor for glycemic control
Funded at Stanford University · NIH-10937825 · Data updated 2026-11-12
This study is working on new types of medicines that could help manage diabetes better by activating insulin receptors, which might lead to easier-to-take oral treatments for people living with diabetes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $772,383 |
| NIH project number | 1DP1DK140025-01 |
| Project ID | NIH-10937825 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diabetes who are seeking better management options.
✕Less likely to help
Patients who do not have diabetes or those whose condition is not responsive to insulin receptor modulation may not benefit from this research.
What this research studies
This research focuses on developing non-peptide ligands that can activate insulin receptors, which could change how diabetes is managed. The project aims to create specific ligands that bind to insulin receptor sites, potentially leading to new oral medications for diabetes. By targeting these binding sites, the research seeks to provide innovative treatment options that could improve glycemic control and overall health for patients with diabetes.
Why it matters
Potential benefit: If successful, this research could lead to more effective and convenient oral treatments for diabetes, improving patients' quality of life.
How similar studies have gone: Previous research has shown promise in developing receptor modulators, but this specific approach is innovative and largely untested.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Chou, Danny Hung-Chieh — Stanford University
- Study coordinator: Chou, Danny Hung-Chieh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.